$NTLA
Intellia Therapeutics, Inc.

2021 Q1 Form 10-Q Financial Statement

#000156459021024947 Filed on May 06, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $6.445M $12.92M
YoY Change -50.1% 23.8%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $13.59M $11.31M
YoY Change 20.16% 7.41%
% of Gross Profit
Research & Development $39.28M $34.65M
YoY Change 13.35% 46.15%
% of Gross Profit
Depreciation & Amortization $1.591M $1.541M
YoY Change 3.24% 18.54%
% of Gross Profit
Operating Expenses $39.28M $34.65M
YoY Change 13.35% 46.15%
Operating Profit -$46.43M -$33.05M
YoY Change 40.48% 38.8%
Interest Expense $220.0K $1.240M
YoY Change -82.26% -33.69%
% of Operating Profit
Other Income/Expense, Net $220.0K
YoY Change
Pretax Income -$46.21M -$31.81M
YoY Change 45.27% 44.99%
Income Tax
% Of Pretax Income
Net Earnings -$46.21M -$31.81M
YoY Change 45.27% 44.97%
Net Earnings / Revenue -716.91% -246.25%
Basic Earnings Per Share
Diluted Earnings Per Share -$687.9K -$630.0K
COMMON SHARES
Basic Shares Outstanding 67.73M 50.51M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $584.1M $250.3M
YoY Change 133.36% -15.61%
Cash & Equivalents $141.5M $80.99M
Short-Term Investments $442.5M $169.3M
Other Short-Term Assets $16.10M $6.100M
YoY Change 163.93% 74.29%
Inventory
Prepaid Expenses
Receivables $953.0K $13.37M
Other Receivables $0.00 $0.00
Total Short-Term Assets $601.1M $269.8M
YoY Change 122.79% -11.16%
LONG-TERM ASSETS
Property, Plant & Equipment $94.10M $42.20M
YoY Change 122.99% 153.16%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $16.70M $0.00
YoY Change
Other Assets $5.000M $2.800M
YoY Change 78.57% -6.32%
Total Long-Term Assets $115.8M $45.00M
YoY Change 157.33% 10.65%
TOTAL ASSETS
Total Short-Term Assets $601.1M $269.8M
Total Long-Term Assets $115.8M $45.00M
Total Assets $716.9M $314.8M
YoY Change 127.73% -8.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.700M $3.900M
YoY Change 123.08% 5.78%
Accrued Expenses $21.22M $13.10M
YoY Change 61.92% 69.39%
Deferred Revenue $12.64M
YoY Change -46.06%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $60.70M $35.30M
YoY Change 71.94% -10.02%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $110.3M $31.70M
YoY Change 247.95% -22.3%
Total Long-Term Liabilities $110.3M $31.70M
YoY Change 247.95% -22.3%
TOTAL LIABILITIES
Total Short-Term Liabilities $60.70M $35.30M
Total Long-Term Liabilities $110.3M $31.70M
Total Liabilities $171.0M $67.00M
YoY Change 155.22% -16.25%
SHAREHOLDERS EQUITY
Retained Earnings -$332.7M
YoY Change 49.0%
Common Stock $580.1M
YoY Change 18.97%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $545.9M $247.8M
YoY Change
Total Liabilities & Shareholders Equity $716.9M $314.8M
YoY Change 127.77% -8.6%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$46.21M -$31.81M
YoY Change 45.27% 44.97%
Depreciation, Depletion And Amortization $1.591M $1.541M
YoY Change 3.24% 18.54%
Cash From Operating Activities -$52.38M -$38.55M
YoY Change 35.88% 79.67%
INVESTING ACTIVITIES
Capital Expenditures $2.412M $845.0K
YoY Change 185.44% -44.88%
Acquisitions
YoY Change
Other Investing Activities -$23.13M $58.29M
YoY Change -139.68% 706.22%
Cash From Investing Activities -$25.54M $57.45M
YoY Change -144.46% 908.74%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $45.26M $4.528M
YoY Change 899.45% 24.43%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 58.60M 4.864M
YoY Change 1104.67% 21.63%
NET CHANGE
Cash From Operating Activities -52.38M -38.55M
Cash From Investing Activities -25.54M 57.45M
Cash From Financing Activities 58.60M 4.864M
Net Change In Cash -19.32M 23.77M
YoY Change -181.3% -302.12%
FREE CASH FLOW
Cash From Operating Activities -$52.38M -$38.55M
Capital Expenditures $2.412M $845.0K
Free Cash Flow -$54.79M -$39.39M
YoY Change 39.09% 71.37%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
141538000
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
80993000
CY2021Q1 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
3745000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
145283000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
80993000
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
901000
CY2020Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
750000
CY2021Q1 ntla Right Of Use Assets Acquired Under Operating Lease
RightOfUseAssetsAcquiredUnderOperatingLease
40394000
CY2020Q1 ntla Right Of Use Assets Acquired Under Operating Lease
RightOfUseAssetsAcquiredUnderOperatingLease
7347000
CY2020Q1 ntla Proceeds From At Market Offerings Unpaid
ProceedsFromAtMarketOfferingsUnpaid
551000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1165300000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
85000000.0
CY2021Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
58000
CY2021Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
70000
CY2021Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
459260000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
437350000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
23000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
22000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
437351000
CY2021Q1 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0
CY2020 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0
CY2021Q1 ntla Available For Sales Securities Noncurrent Maturing Beyond Year Five
AvailableForSalesSecuritiesNoncurrentMaturingBeyondYearFive
0
CY2020Q4 ntla Available For Sales Securities Noncurrent Maturing Beyond Year Five
AvailableForSalesSecuritiesNoncurrentMaturingBeyondYearFive
0
CY2021Q1 ntla Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
10010000
CY2020Q4 ntla Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
11008000
CY2021Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6244000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
10920000
CY2021Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2833000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1876000
CY2021Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2128000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1750000
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21215000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
25554000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2130000
CY2021Q1 ntla Increase In Accounts Receivables
IncreaseInAccountsReceivables
953000
CY2021Q1 ntla Decrease In Accounts Receivables
DecreaseInAccountsReceivables
2130000
CY2021Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
953000
CY2021Q1 us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
-5558000
CY2021Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
68373000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4620000
CY2020Q1 ntla Increase In Accounts Receivables
IncreaseInAccountsReceivables
9765000
CY2020Q1 ntla Decrease In Accounts Receivables
DecreaseInAccountsReceivables
1017000
CY2020Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
13368000
CY2020Q1 us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
-3151000
CY2020Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
25659000
CY2021Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
5558000
CY2020Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
3151000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6424000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4157000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
193936
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
23.98
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
259839
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
57.71
CY2021Q1 ntla Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Cancelled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod
11035
CY2021Q1 ntla Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Cancelled In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue
27.59
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
442740
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
43.69
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
17800000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
36.64
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.96
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
54800000
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
300000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.009
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.010
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.720
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.667
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6977440
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
15.43
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1645823
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
57.94
CY2021Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1014569
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
13.15
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
129393
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
20.71
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7479301
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
25.00
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
413258000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2734966
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
86900000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-46205000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-31806000
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
67183000
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
50491000
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.69
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.63
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7922000
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7491000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
527072000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
13340000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6424000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-13000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-46205000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
545873000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
269881000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
336000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4157000
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
112000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-31806000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
247759000

Files In Submission

Name View Source Status
0001564590-21-024947-index-headers.html Edgar Link pending
0001564590-21-024947-index.html Edgar Link pending
0001564590-21-024947.txt Edgar Link pending
0001564590-21-024947-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
ntla-10q_20210331.htm Edgar Link pending
ntla-10q_20210331_htm.xml Edgar Link completed
ntla-20210331.xsd Edgar Link pending
ntla-20210331_cal.xml Edgar Link unprocessable
ntla-20210331_def.xml Edgar Link unprocessable
ntla-20210331_lab.xml Edgar Link unprocessable
ntla-20210331_pre.xml Edgar Link unprocessable
ntla-ex101_147.htm Edgar Link pending
ntla-ex102_148.htm Edgar Link pending
ntla-ex103_149.htm Edgar Link pending
ntla-ex311_6.htm Edgar Link pending
ntla-ex312_8.htm Edgar Link pending
ntla-ex321_7.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending